Lixte Biotechnology Holdings, Inc. (LIXT)
NASDAQ: LIXT · Real-Time Price · USD
2.880
+0.030 (1.05%)
Apr 9, 2026, 1:43 PM EDT - Market open

LIXT Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Selling, General & Admin
4.852.854.194.964.98
Research & Development
0.250.730.91.351.74
Total Operating Expenses
5.113.575.096.316.72
Operating Income
-5.11-3.57-5.09-6.31-6.72
Interest Income
0.010.010.020.010
Interest Expense
-0.01-0.02-0.02-0.01-0.01
Other Non-Operating Income (Expense)
-0.9-00-0-0
Total Non-Operating Income (Expense)
-0.9-0.010-0-0.01
Pretax Income
-6.01-3.59-5.09-6.31-6.73
Net Income
-6.08-3.59-5.09-6.31-6.73
Net Income Attributable to Preferred Dividends
0.07----
Net Income to Common
-6.08-3.59-5.09-6.31-6.73
Shares Outstanding (Basic)
52221
Shares Outstanding (Diluted)
52221
Shares Change (YoY)
115.21%17.41%21.10%17.41%19.48%
EPS (Basic)
-1.26-1.59-2.66-3.99-5.00
EPS (Diluted)
-1.26-1.59-2.66-3.99-5.00
Shares Outstanding
8.792.252.251.661.37
Free Cash Flow
-3.07-3.24-4.29-4.61-4.14
Free Cash Flow Per Share
-0.63-1.44-2.24-2.92-3.07
EBITDA
-5.11-3.57-5.09-6.31-6.72
EBIT
-5.11-3.57-5.09-6.31-6.72
Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q